April 24, 2018

George Yeh
President
Taiwan Liposome Company, Ltd.
11F-1, No. 3 Yuanqu Street
Nangang District
Taipei City, Taiwan 11503
Republic of China

       Re: Taiwan Liposome Company, Ltd.
           Amendment No. 1 to Registration Statement on Form F-1
           Filed April 16, 2018
           File No. 333-223090

Dear Mr. Yeh:



      We have reviewed your amended registration statement and have the
following
comments. In some of our comments, we may ask you to provide us with
information so we
may better understand your disclosure.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comments apply to your facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information you
provide in response to these comments, we may have additional comments. Unless
we note
otherwise, our references to prior comments are to comments in our February 27,
2018 letter.

Form F-1 Filed April 16, 2018

Cover Page

1.     Although Rule 430A of the Securities Act of 1933 permits registrants to
omit certain
       pricing-related information from a registration statement that is
declared effective, your
       filing must include the amount of securities to be offered in a
pre-effective amendment.
 George Yeh
Taiwan Liposome Company, Ltd.
April 24, 2018
Page 2
      Accordingly, revise your registration statement to disclose the number of
securities you
      are registering, rather than registering a dollar amount. For guidance,
refer to Question
      227.02 of Compliance and Disclosure Interpretations for Securities Act
Rules.
Prospectus Summary
Pipeline, page 3

2.    The table of your product candidate pipeline on pages 4 and 79 should
reflect the actual,
      and not the anticipated, status of your pipeline candidates as of the
latest practicable date.
      The table currently suggests that TLC590 is in the midst of Phase I
trials but your
      disclosure indicates that you filed an IND application for in April 2018
and have not
      initiated clinical trials. Please revise the table to reflect the actual
status of TLC590.
Risk Factors
Delays in clinical trials are common and have many causes, and any delay could
result in increas
ed costs..., page 17

3.    We note your disclosure on page 17 that an independent safety monitoring
committee
      requested a temporary recruitment pause of TLC399. Please include
disclosure in your
      prospectus summary indicating that TLC399 is subject to a temporary
recruitment pause,
      revise the pipeline chart on pages 4 and 79 to indicate that TLC399 is
subject to a
      temporary recruitment pause, and revise your Business section to explain
the particular
      findings or concerns that led to the temporary recruitment pause.
Principal Shareholders, page 136

4.    We note that in response to comment one of our letter dated February 27,
2018 you have
      updated the beneficial ownership as of March 31, 2018. However, we note
that
      information with respect to beneficial ownership be your directors,
executive officers,
      statutory auditors and holders of more than 5% of your outstanding common
shares is as
      of October 2, 2017. Please revise your registration statement to provide
beneficial
      ownership information for your directors and members of your
administrative, supervisory
      or management bodies as of the most recent practicable date. See Item 6.E
of Form 20-F.
       You may contact Franklin Wyman at 202-551-3660 or Lisa Vanjoske at
202-551-3614 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Jeffrey Gabor at 202-551-2544 or Erin Jaskot at 202-551-3442 with any
other questions.


FirstName LastNameGeorge Yeh
                                                             Division of
Corporation Finance
Comapany NameTaiwan Liposome Company, Ltd.
                                                             Office of
Healthcare & Insurance
June 16, 2017 Page 2
cc: Charlie Kim, Esq.
FirstName LastName